News Release
-
2023/11
Phase II clinical trials of M201-A injection for patients with heart failure and renal dysfunction were initiated in the first semester.
-
2022/03
A co-development agreement for M201-A injection for heart failure in Japan was signed.
-
2021/01
A Phase I repeated-dose study of M201-A injection was completed. We confirmed the effects of M201-A on Na diuresis and improvement of renal function in humans with mild renal dysfunction.
-
2020/03
A dose-escalation, placebo-controlled, double-blind, randomised Phase I repeated-dose study of M201-A hydrochloride injection in healthy adults was initiated.
-
2019/05
We initiated an early Phase II clinical trial of single-dose M201-A injection in patients with paroxysmal atrial fibrillation.
-
2018/09
The project ‘Development of a novel treatment for atrial fibrillation with M201-A hydrochloride’ was adopted by the Japan Agency for Medical Research and Development (AMED).
-
2017/11/30
A Phase I clinical trial of M201-A injection has been completed.
-
2017/06/21
The ‘Investigation of the safety and efficacy of M201-A hydrochloride injection for the treatment of atrial fibrillation - Phase II clinical trial in early phase’ was accepted by the National Agency for Research and Development (AMED).
-
2016/12
The ‘Report of Research Results in FY 2015’ of the Support Program for Optimal Deployment of Research Results [A-STEP] (Medical Field Research Results Deployment Project) has been released (→Research Results Report for FY 2016 is here).
-
2013/12/03
The ‘Research Project: Atrial Fibrillation and Flutter Drug’ was adopted by the Japan Science and Technology Agency (JST) as an A-STEP project.